Please ensure Javascript is enabled for purposes of website accessibility

Senator Takes Aim at Biogen's New Alzheimer's Drug

By Todd Campbell - Jun 8, 2021 at 3:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sen. Ron Wyden calls Aduhelm's $56,000 price tag "unconscionable."

A tweet from Sen. Ron Wyden today blasted Biogen's (BIIB -0.29%) decision to price its newly approved Alzheimer's drug, Aduhelm, at $56,000 per year. The Democratic senator from Oregon suggested the price is particularly unreasonable given questions regarding its efficacy, and he said Medicare should be granted the ability to negotiate prices directly with drugmakers to keep costs in check.

A senior man looking into his empty wallet.


The Food and Drug Administration granted conditional approval to Aduhelm today, despite a key advisory committee recommending against approval last fall. The committee's concern stemmed from Aduhelm's inability to clearly demonstrate it can meaningfully improve cognitive function in Alzheimer's patients during clinical trials.

Instead of basing it's approval decision on Aduhelm's impact on Alzheimer's disease symptoms, the FDA granted the drug a green light based on its ability to reduce amyloid beta plaque buildups in the brain. For years, researchers have suggested these buildups contribute to the disease's progression. But in the past, trials of medications targeting amyloid beta have failed to demonstrate that reducing plaques improves outcomes.

Nevertheless, Biogen believes reducing amyloid beta plaques offers newfound hope to over 6 million Americans diagnosed with the disease, making Aduhelm worth its $56,000 per year price. No new drugs targeting Alzheimer's disease have been approved in the past 20 years, and it is the sixth leading cause of death annually.

On Twitter, Sen. Wyden reacted to Biogen's decision by tweeting: "It's unconscionable to ask seniors and taxpayers to pay $56,000 a year for a drug that has yet to be proven effective. Medicare must be able to negotiate a fair price for prescription drugs."

Unlike private insurers, Medicare Part D is unable to negotiate directly with drugmakers, making it dependent on private insurers to negotiate lower prices. Conceivably, Medicare could wrangle even lower prices if it were allowed to aggregate all Part D recipients during negotiations.


Todd Campbell has no position in any of the stocks mentioned. His clients may or may not have positions in the companies mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$220.34 (-0.29%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.